| Sign In to gain access to subscriptions and/or personal tools. |
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonistDepartment of Neurology, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands, bw.vanoosten{at}vumc.nl
Department of Neurology, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands
Department of Gastroenterology and Hepatology, Academic Medical Centre, P.O. Box 22700, 1100 DE Amsterdam, the Netherlands
Department of Neurology, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabino id recepto r antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabino id system might indeed be relevant to disease pathogenesis in MS.
Key Words: appetite depressants cannabinoid receptor antagonist endogenous cannabinoids multiple sclerosis obesity
Multiple Sclerosis, Vol. 10, No. 3,
330-332 (2004) This article has been cited by other articles:
|
|||||||||||||||||||||||||||

